News and Analysis | Published:

Tissue-agnostic cancer drug pipeline grows, despite doubts

Nature Reviews Drug Discovery volume 17, pages 227229 (2018) | Download Citation

The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer indication, but biological complexity may limit this approach.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Ken Garber in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing